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Background: Cryoablation (Cryo) has augmented radiofrequency (RF) as the ablation energy choice for
most supraventricular tachycardias (SVT). Although initial acute results and more recent, but limited,
3–36-month follow-up studies have been reported, more longer follow-up information is required to
determine actual efficacy.
Methods: Data from patients with structurally normal hearts who underwent reentrant forms of
SVT ablation at our institution from January 2005 to December 2009 were reviewed. These included
demographics, clinical and electrophysiologic findings, and ablative energies used. Following apparent
acute success, all patients were then reevaluated for any potential recurrences of SVT or preexcitation up
to 5 years later.
Results: A total of 155 patients (83 male) were reviewed (mean age 13.4 ± 3.7 years). Ablations
were predominantly right-sided (75%). Atrioventricular reciprocating tachycardia was seen in 74%
and atrioventricular node reciprocating tachycardia (AVNRT) in 17% of patients. For concerns of
atrioventricular node integrity, Cryo ± RF was user-preferred for anteroseptal accessory fiber locations
and AVNRT. Acute success rate was 98% and chronic 83.2% over the next 5 years. Among patients with
accessory pathways, recurrence was pathway number and location dependent: significantly higher (P <
0.05) if they were right anterior-anteroseptal, multiple, or with a broad-distribution pattern. There were
no significant differences in recurrence rates with use of RF or its combination with Cryo.
Conclusion: Radiofrequency ablation and Cryo are both effective therapies for pediatric patients.
Although use of Cryo with RF in combinationmay enhance safety while affording comparable success, risk
of recurrence still persists in the current era among patients depending on accessory pathways connection
location and characteristics. (PACE 2012; 35:711–717)
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Introduction
Radiofrequency catheter ablation (RFA) has
revolutionized the treatment of diverse supraven-
tricular tachycardias (SVT) in children.1 Although
developed in the 1980s and widely applied in the
1990s, formalized guidelines for its use in clinical
practice were not developed until recently.2
Based on data from the Pediatric Radiofrequency
Catheter Ablation Registry, acute failure rates fell
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from 9.6% in the early 1990s to 4.3% at the end of
the decade.3
RFA, however, can cause complications
including thromboembolic events resulting in
neurological damage, coronary artery injury,
atrioventricular (AV) node injury, conduction
block,4 and even death.5–7 Cryoablation (Cryo)
is a newer energy modality of catheter ablation
which has proven to be safe in many studies.8,9
Previous studies have reported acute success rates
of only 69–92% which is less than that reported
for RFA10,11 and higher arrhythmia recurrence
compared to RFA.8
Most of the initial RFA and Cryo studies
reported only acute success results. More recent
but limited combined RFA/Cryo studies have
reported from 9 to 35% recurrence rates.12–14 But,
there is a paucity of studies comparing early and
late ablative success rates using RFA or Cryo or
combinations of both in pediatric patients with
structurally normal hearts. We sought to identify
potential risk factors for SVT recurrence after
initial successful ablation in the current era.
C©2012, The Authors. Journal compilation C©2012 Wiley Periodicals, Inc.
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Methodology
This was a retrospective study conducted at
The Children’s Hospital of Michigan, Division
of Cardiology. The study was approved by the
institutional review committee at Wayne State
University School of Medicine, Detroit Medical
Center. The inclusion criteria were patients with
reentrant forms of SVTwith documented evidence
by electrocardiogram (EKG), Holter, or event
monitor referred for an initial catheter ablation.
Patients with repeat procedures were excluded.
To allow for a degree of consistency in comparison
of energy sources, per se, patients with structural
congenital heart defects or previous ablations
were excluded. As such, only patients with
atrioventricular node reciprocating tachycardia
(AVNRT), atrioventricular reciprocating tachycar-
dia (AVRT), sinus reentry, as well as His bundle
reentrant forms of SVT were included in this
study. Also, since the purpose was to evaluate
energy delivery efficacy in discrete select regions
in deference to performance of a more extensive
linear “maze,” patients with primary atrial muscle
tachycardias such as flutter/fibrillation also were
not included. Ectopic atrial tachycardia was not
included as it was considered to be an automatic
tachycardia.
All clinical, intracardiac electrophysiological
study (EPS) and follow-up data were reviewed.
The demographic and clinical data collected
included patient’s age, gender, ethnicity, height,
weight, body surface area, clinical manifestations,
as well as presence or absence of preexcitation
at rest and on exercise stress testing. EPS data
included site and number of locations of accessory
pathways (APs), and use of RFA or Cryo or both.
Follow-up data at 1–2 weeks and from 3 to 77
months later included recurrence of symptoms;
results of treadmill exercise stress testing; and
15-lead EKG, Holter, or telephone event monitor
reports and any repeat EPS procedures.
All patients underwent EPS under the same
protocol by two established pediatric electro-
physiologists. All procedures were performed
under standard general anesthesia. Established
techniques using multielectrode catheter place-
ment for intracardiac pacing and mapping were
performed in all cases. A standard flexible
quadripolar roving electrode catheter was used for
selective AP site mapping as required. A three-
dimensional mapping system (St. Jude Medical,
Minnetonka, MN, USA) was used to define
anatomical and electrical landmarks to limit
fluoroscopic imaging support for all patients post
mid-2007.
Among patients with overt preexcitation
standard mapping for prograde AP conduction
to delineate location was conducted prior to
initiation of stimulation protocols. The region
of electrical interest was established to include
atrial and ventricular activation. For this study,
the now standard, albeit somewhat arbitrary,
AP site map was used to define general AP
locations, with the realization that AP connections
are not necessarily discrete and separate as the
AV annulus has limited definable boundaries.3,15
Multiple pathways were defined by established
techniques of catheter mapping 1–3 cm apart
or change in any preexcited QRS morphology
following ablation at different sites or induction
of another form of tachycardia with a different
QRS morphology or axis.18 Since fluoroscopic
mapping-based identification of presence of mul-
tiple APs is inexact, patients in whom mapping
of AP connections and ablations were performed
across several or adjoining traditional fluoroscopic
locations (e.g., anterior-anteroseptal) were said
to have broad-distribution fibers, ostensibly with
wide atrial and ventricular insertions, in deference
to more discrete and, by inference, compact APs.19
Standard programmed electrical stimulation
(PES) protocols were instituted specifically to only
induce tachycardia, not to induce nonclinical
atrial flutter/fibrillation (AF). These included
single, double, and burst atrial extra stimuli at
standard variable drive-paced cycle lengths (all
>200 ms), both with and without isoproterenol
infusion (0.1 mcg/min), as required for arrhyth-
mia induction. Once the SVT mechanism (e.g.,
AVRT or AVNRT) was identified and any APs
located by standard catheter mapping, RFA and/or
Cryo ablations were performed. As part of the
established EPS protocol at our institution, risk
stratification of each patient with evaluation of
refractory periods, inducibility of arrhythmias,
and concomitantly measured hemodynamics, es-
pecially among patients with overt preexcitation
and potential for sudden death, was performed.
This also permitted amore accurate determination
of “success” as the entire EPS stimulation protocol
was repeated following ablation. In instances of
induced hemodynamic instability, cardioversion
was performed.
Each RFA application was performed up to
60 seconds to attain a tissue temperature from
50◦C–70◦C (Boston Scientific, Natick, MA, USA)
and each Cryo was performed using a 4-mm Cryo
catheter for up to 4 minutes using the two-tiered
approach of initial tissue chilling at –30◦C for
several seconds followed by cellular disruption
achieved at a temperature of −70◦C (CryoCath,
Medtronic). Once tachycardia occurred, any spon-
taneous deterioration to AF was recorded. All pa-
tients were observed for 60 minutes following ap-
parent successful ablation. This was followed by
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a full repeat PES with and without isoproterenol
to evaluate inability to reinduce any SVT, as well
as administration of adenosine (for AVRT cases)
to confirm evidence of any residual accessory
orthodromic connections. Recurrence required
additional ablation. Success was therefore defined
as meeting several criteria following a 60-minute
postablation waiting interval: (1) A normal QRS
in all patients and no visible preexcitation among
those patients with previous preexcitation; (2)
Inability to reinduce SVT in spite of repeat PES
with andwithout isoproterenol infusion among all
patients; (3) No evidence of residual preexcitation
following adenosine administration. Retrograde
VA conduction, which can be a common ancillary
finding in children, was not uniformly tested in all
patients postablation and therefore not included as
a success criteria per se.
After the procedure, as part of hospital
policy, patients were observed overnight and a
standard 15-lead EKG to reconfirm a normal QRS
and echocardiogram/Doppler to evaluate valve
integrity were performed the next day prior to
discharge. All patients were then reevaluated from
1 to 2 weeks followed by 1–3 months later and
then on a recommended yearly basis for any SVT
recurrences. All follow-up clinical evaluations
included a standard 15-lead EKG. If patients had
any recurrence of clinical symptoms, telephone
event and/or Holter monitor recording equipment
was provided for confirmation depending on the
discretion of the cardiologist. For SVT recurrence,
medical management was initiated before repeat-
ing the electrophysiology (EP) procedure. For
statistical analysis, patients were divided into two
groups: Group 1, those with SVT recurrences and
Group 2, those without SVT recurrences. Group
1 patients also included those with a return of
preablation preexcitation with or without SVT.
Statistics
This was a retrospective study. All data were
reported as mean and standard deviation for
continuous variables and frequency for categorical
variables. The two groups were compared using
independent sample t-test, Mann-Whitney U test,
Fisher’s exact or χ2 tests depending on the
distribution of the data. All statistical analyses
were performed using SAS software version 9.1
(SAS Institute, Cary, NC, USA).
Results
A total of 155 patients with structurally
normal hearts underwent catheter ablation at our
institution for the indicated forms of SVT from
January 2005 to December 2009. Of these, 83
were males and 72 were females. Mean age at
catheterization was 13.4 ± 3.7 years. Based on
listed ethnicity, 99 (64%) were of European-, 34
(22%) African-, five (3%) Mid-Eastern-, and one
(1%) Asian-American ancestries.
Of the initial 155 patients, acute success
was achieved in 153 (98%). Later, 24 patients
(16.8%) developed recurrence of SVT or overt
preexcitation at a mean follow-up interval of
38 months (Group 1), whereas 129 had no
evidence of either recurrence (Group 2). Median
follow-up interval was 41 months (1–77 months)
and 21 patients (13.5%) were lost to follow-
up. Of the remaining 134 patients not lost to
follow-up, clinical information was available on
108 patients (81%) at 2 years, 82 (61%) at 3
years, 52 (39%) at 4 years, and 29 (22%) at
5 years postablation. Although patients in the
recurrence group were younger than those in
the nonrecurrence group (P < 0.05), the other
demographic distributions including weight, sex,
and race were not significantly different between
both groups (Table I). Pre-EPS, overt preexcitation
on resting EKG was seen in 82 patients (53%).
This included 13 (50%) in Group 1 and 69 (54%)
in Group 2. This was not significantly different
(P = 0.8). Tachycardia types were typical for a
pediatric population: 74% atrioventricular reentry
(AVRT) with accessory bypass fibers, 17% “slow-
fast” AV node (AVNRT), 5% sinus node, and 4%
His bundle reentry.
Fifty-five patients (36%) had more than
one accessory connection catheter map location
including 58% of Group 1 and 31% of Group 2
(P = 0.01). Among these patients, multiple
accessory connection locations encompassing
both right and left valve locations were found
Table I.
Patient Demographics between Groups
Recurrence No-recurrence
(n = 26) (n = 129) P- value
Age 11.7 ± 3.6 13.6 ± 3.6 <0.05
Weight 54 ± 21 53 ± 22 0.9
Sex—Male 10 (39%) 73 (57%) 0.1
European 17 (65%) 82 (64%) 0.9
ancestry
African ancestry 7 (27%) 27 (21%) 0.6
Mid-Eastern 1 (4%) 4 (3%) 1.0
ancestry
No significant difference between the two groups in terms of
gender, weight, and ethnicity. Patient age, however, was
significant. There was only one patient of Asian ancestry. That
patient had no recurrence.
Value expressed as mean ± standard deviation or as number
(percentage).
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in 10% whereas broad-distribution connections
were found in 26%. Of these latter, the most
common was an overlap between right anterior
and anteroseptal catheter-mapped regions. The
average number of mapped AP locations in Group
1 was 1.7± 0.7 and 1.4± 0.6 in Group 2 (P< 0.05).
Ablations were required in variable areas
depending on accessory fiber locations or mech-
anism of SVT. In this review, AVNRT was consid-
ered a right-sided tachycardia which contributed
to the difference between right and left loca-
tions. Therefore, ablations were predominantly
performed on the right side: 112 patients (75%)
versus left side in 54 patients (25%). Among
all patients with right-sided tachycardia foci,
anteroseptal locations were seen in 42 patients
(20%), anterior in 33 (15%), and midseptal in
30 (14%); AVNRT was seen in 35 (17%), sinus
node reentry in 11 (5%), and His bundle in
five (4%). AVNRT ablations were performed to
either eliminate or modify “slow” AV pathway
conduction properties.
Among AVRT mechanisms, SVT recurrence
was significantly higher among patients following
right anteroseptal fiber ablation with a 33%
recurrence rate (P < 0.01 between both groups)
and an odds ratio of 4.2. Recurrence was not
significantly higher in the other fiber locations,
including AVNRT (Table II). However, among
patients with multiple or broad-distribution AP
distributions, 27% had recurrences (P = 0.01
between both groups) and an odds ratio of 3.0.
During the EPS, RFA and/or Cryo were
used depending on the location of the APs
and at the discretion of the electrophysiologist
performing the procedure. With concern for AV
Table II.
Accessory Fiber Locations/Ablation Sites between
Groups
Recurrence No-recurrence
Fiber Locations (n = 42) (n = 173) P-value
Right anteroseptal 14 (33) 28 (16) <0.01
Right anterior 8 (19) 25 (15) 0.1
Midseptal 4 (10) 26 (15) 0.3
Left posterolateral 6 (14) 48 (28) 0.2
AVNRT 5 (12) 30 (17) 0.8
Sinus reentry 2 (5) 9 (5) 1.0
His bundle 3 (7) 7 (4) 0.2
Recurrence is significantly higher in patients with right
anteroseptal fiber locations (P < 0.01). No other fiber locations
were associated with increased recurrence.
Value expressed in number (percentage).
node integrity, RFA and Cryo were preferably
used for AP locations away from and in close
proximity to the normal conduction pathway,
respectively. For most of the fiber locations close
to the conduction pathway, like AVNRT, Cryo
was used first for cryomapping and cryoablation.
RFA was then used in the same location when
it was deemed safe by cryomapping or for
placing linear lesions further away from the
conduction pathway. Patients were divided into
three groups based on type of energy source
used for ablation. RFA alone was used in 87
patients (107 fiber locations), Cryo alone in nine
patients (11 fiber locations), and both RFA/Cryo
were used in 59 patients (97 fiber locations).
Cryo with/without RFA was preferably used for
AVNRT and right anteroseptal fibers to optimize
avoidance of AVN conduction damage. RFA alone
was preferred for left-sided fibers. When required
due to fiber location, coronary sinus RFA was
also performed (Table III). The number of RFA
ablations applied was higher in the RFA + Cryo
group compared to RFA group, indicating that
this group required more ablations to achieve
success. The number of Cryo, though higher in
RFA+Cryo group compared to Cryo alone, did not
reach statistical significance. Electroanatomic 3D
mapping was used for all patients post mid-2007.
However, comparison on recurrence cannot be
made between those patients with and without 3D
mapping as the follow-up period was significantly
higher for patients without 3D mapping compared
to those in whom it was used, resulting in higher
recurrences in the pre-2007 group without use of
3D mapping.
There were 34 African-American patients
forming 22% of the study group, including 16
males (47%). Of these, 22 (65%) had overt
preexcitation. Seventeen (50%) of them exhibited
multiple or broad-distribution right-sided AP
connections compared to only 31% in the non-
African-American races. This difference was
significant (P = 0.04). A total of 51 AP fiber
locations were identified among this ethnic group,
including 40 (78%) right-sided and 11 (22%) left-
sided fibers. Among the right-sided APs, right
anterior were seen in 12 (30%), right anteroseptal
in eight (20%), and midseptal in nine (23%).
AVNRT was seen in seven (17%), sinus reentry
in two (5%), and His reentry in two (5%).
Acute success rates as defined earlier (inabil-
ity to reinduce any arrhythmia, no preexcitation
with adenosine, and a normal QRS morphology)
was 98%. Both Cryo with/without RFA Groups
had 100% acute success. Of the two patients in the
RFA-only Group who had acute failure, one had
both right anterior and anteroseptal fibers and the
other had left posterolateral fibers. Both patients
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Table III.
Accessory Fiber Locations between Groups Based on Type of Energy Source Used for Ablation
Fiber Locations RFA (n = 107) Cryo (n = 11) RFA + Cryo (n = 97) P-value
Number of patients 87 9 59
Right anteroseptal 13 (12) 3 (27) 26 (27) < 0.01
Right anterior 16 (15) 0 (0) 17 (18) 0.1
Midseptal 14 (13) 0 (0) 16 (16) 0.8
Left posterolateral 44 (42) 0 (0) 10 (10) < 0.01
AVNRT 10 (9) 5 (46) 20 (21) < 0.01
Sinus reentry 8 (7) 1 (9) 2 (2) 0.2
His bundle 2 (2) 2 (18) 6 (6) 0.36
Number of RFA 13 ± 11 – 21 ± 16 0.01
Number of Cryo – 7 ± 5 11 ± 8 0.5
Cryo with or without RFA was preferably used for right anteroseptal fiber locations and AVNRT while RFA alone was preferably used for
left-sided fiber locations.
P-value comparing RFA group with RFA + Cryo group.
Value expressed in number (percentage) or mean ± standard deviation.
had persistent preexcitation after the ablation, but
no tachycardia could be induced with PES after
waiting for an hour and parents deciding against
further ablations. Following initial success, 16.8%
of patients had SVT/preexcitation recurrences
during the follow-up interval. Recurrence risk
was not significantly different with use of RFA
(14%), Cryo (22%), or both (20%). By survival
analysis, no significant difference in recurrence
was found between the three groups (Fig. 1). The
EPS were performed by two electrophysiologists
in our institution and the recurrence risk was
not significantly different between them. Using
regression analysis, recurrence risk was highest in
patients with right anteroseptal fibers.
Rhythm complications of flutter/fibrillation
occurred in five patients during PES with rapid
ventricular response and hemodynamic deterio-
ration that required cardioversion. There were
no AV conduction problems associated with
any initial ablation. There was no evidence of
coronary sinus or AV valve problems clinically
or by ultrasound. There were no complications of
stroke, coronary artery injury, and no deaths were
encountered.
Discussion
SVT is a frequently encountered arrhythmia
in pediatric patients. Medical therapy requires
patient and family compliance which is often
less than optimal and antiarrhythmic drugs can
be proarrhythmic. Although surgical ablation
was an available alternative previously, catheter-
delivered RFA and Cryo have now revolutional-
ized treatment modalities. The safety and efficacy
has been improving over the years with the
Figure 1. Kaplan-Meyer curve comparing freedom from
recurrence between three groups based on type of
energy source used. There is no significant difference
in recurrence between the three groups.
learning curve phenomenon as applied to use in
children.14,15
RFA is the widely used older energy source
for ablation. The success has been improving over
the years. The Pediatric Radiofrequency Catheter
Ablation Registry reported an improvement in the
initial success rates from 90.4% (1991–1995) to
95.2% (1996–1999) for RFA among all patients.3
Our report has a better acute procedural success
rate for RFA at 98%. Cryotherapy is the newer
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modality of treatment. An acute success rate of
87.1% for cryotherapy has been reported, which
is less than that for RFA with success rates for
AVNRT ablation higher than for AVRT (95.5% vs
62.5%, P < 0.05).10 In our study, with Cryo alone,
the acute success ratewas 100%, but only a limited
number of patients were in this group. For many
of our patients, RFA was used together with Cryo
and the success rate was also 100%. The reason for
such a high acute success rate in our study reflects
use of RFA along with Cryo in locations where
RFA could be used safely.
Rates of initial success also depended on
AP location. In our patient population, among
those with AVRT, the fiber locations were
predominantly right-sided (66%). This is in
contradistinction to the findings of the initial
Prospective Assessment after Pediatric Catheter
Ablation as well as a more recent study in
which right-sided pathways were found in only
17–30% of patients.4,20 Although the “anatomical
maps” do help to standardize ablation catheter
locations by fluoroscopy, they are somewhat
arbitrary and not based on any direct histological
evidence. Previous studies have reported multiple
AP fibers in 5–20% of patients based on clinical
findings.20 However, right-sided AP connections
are anatomically different from left. The associated
folding of the atrium over the ventricle, inherent
anatomical variability of the right-sided A-V
ring, AP physical characteristics, and orientation
relative to atrial and ventricular myocardium
may all contribute to an inherent overlap among
the sites, especially on the right. Wide AP
branching and spatial separation of any two APs,
as shown in histologic studies, may present with
a clinical picture of multiple or broad-distribution
connections, hindering effective catheter mapping
and ablation.16 In the previous era of surgical
ablation, an extensive valve annuloplasty was
often performed to ensure AP interruption.17 In
this regard, patients with such connections may
be expected to have less optimal ablation results
than those with more discrete connections.18,19
A comparison between our data and the
previous reports mentioned earlier also shows an
interesting discrepancy in patient ethnicity. Our
database shows that 22% of our patients were
of African-American ancestry compared to 3–7%.
There were more patients with broad-distribution
or multiple fiber locations as noted earlier. Our
data, therefore, suggest that ethnicity may be an
important component of AP type and location
and, by inference, tachycardia recurrence. Since
there are regional ethnic population diversities
across the United States, any one pediatric EP
center may have limited exposure to any one
ethnic group. In this regard, we agree with the
recent report by Hsu et al. that ethnicity may
be an important variable contributing to different
reported AP locations, successes, and recurrences
among different institutions.21 However, a larger
multi-institutional/multi-ethnic population study
will be required to further evaluate this concept.
We purposely used a very broad definition
of “recurrence” to include both only recurrent
preexcitation as well as bona fide tachycardia.
In this regard, the late 5-year recurrence rate
in our study was 16.8%. Previous studies have
reported recurrence rates varying from 4.7 to
45%, with RFA at 4.7–8.2%12,13 and Cryo even
higher at 13–45%.14,22 In our current study, no
significant differences in recurrence rates were
noted for use of RFA or RFA + Cryo (14
and 20% respectively, P = 0.5). The Cryo-only
group had recurrence rate of 22% which was
not significantly different compared to others,
but as this group had very limited number of
patients, this comparison may not be adequately
powered. The use of RFA combined with Cryo
could have improved the overall success rates in
our study group. The recurrence rate also varied
depending on substrate location. Although there
has been improvement over the last two decades,
the success rate for RFA ablation of right is less
than for left-sided pathways, 90% versus 98%.4
From the international registry, a 75% success rate
was reported for right septal fibers.11 In our study,
higher recurrence was noted for right-sided fibers
with right anteroseptal fibers (33%), right anterior
(24%), left-sided fibers (20%), and AVNRT (14%).
AV block has been reported to occur in
1.2% of patients following ablation, mostly for
AVNRT and septal accessory pathways.4 Unlike
RFA, Cryo has been associated with a decreased
incidence of reported complications. It has been
shown that cooling of the myocardium to −30◦C
results in reversible tissue modification.23 This
adds a theoretical benefit of predetermining any
potential adverse problems prior to definitive
cellular disruption once the temperature reaches
−70◦C. In animal studies, cryoablated sites were
more homogeneous and showed viable myocytes
with fibrotic tissue changes but no signs of chronic
inflammation.24 Cryo has also been shown to
have better catheter adherence and spares the
endothelial lining leading to less thrombogenicity
compared to RFA.25,26 Use of Cryo for fiber
locations close to AV node and limiting RFA
to safer regions could be the cause for the low
incidence of complications in our study.
Unlike previous studies, we have reported
long-term follow-up in pediatric patients.We have
used RF with Cryo which is different compared to
previous studies. Compared to previous studies,
although our overall success rates seem to be
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similar, we had many patients with right-sided
APs and we have higher success rates for these
fibers. We thus propose that use of RFA with Cryo
together would increase success rates compared to
either energy source alone for those fiber locations
that have traditionally been known to have poor
ablation success.
Limitations
This was a single-center retrospective study
with a relatively small number of patients in the
Cryo-only group. Also, our patient demographics
and accessory fiber locations differ from other
studies making generalization of the results
difficult. Further multicenter prospective studies,
including ethnic diversity, will be needed to
validate the findings.
Conclusion
RFA and Cryo are safe and efficacious
treatment options for pediatric patients with
SVT. They are associated with excellent acute
procedural success. But since first applied,
chronic efficacy of ablation therapies in the young
have not yet been well established. Our report
demonstrates that in spite of apparent acute
success, the risk of late recurrence, either as QRS
preexcitation and/or arrhythmias, persists in the
current era especially among patients with broad-
distribution, multiple and those with anteroseptal
accessory fiber locations. Use of Cryo with RF in
combination may enhance safety while affording
comparable success, especially for fiber locations
that have been traditionally known to have higher
recurrence rates.
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